Fibrinogen ( DrugBank: Fibrinogen )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
14	Chronic inflammatory demyelinating polyneuropathy	1
65	Primary immunodeficiency	3

14. Chronic inflammatory demyelinating polyneuropathy

---

Clinical trials : 175 /  Drugs : 161 - (DrugBank : 41) / Drug target genes : 13 - Drug target pathways : 24

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03801135 (ClinicalTrials.gov)	October 3, 2018	4/10/2018	Changes in Haemostasis After Therapeutic Plasmapheresis With Citrate Anticoagulation	A Prospective Interventional Study to Investigate Changes in Haemostasis After Therapeutic Plasmapheresis With Citrate Anticoagulation With or Without Coagulation Factors Replacement	Humoral Rejection;Guillain-Barre Syndrome;Miller Fisher Syndrome;CIDP;Good Pasture Syndrome;Hyperviscosity Syndrome	Drug: Fibrinogen concentrate;Other: Fresh Frozen Plasma	University Medical Centre Ljubljana	NULL	Recruiting	18 Years	N/A	All	20	N/A	Slovenia

65. Primary immunodeficiency

---

Clinical trials : 500 /  Drugs : 614 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 217

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2011-004154-25-IT (EUCTR)	25/06/2013	20/02/2013	Clinical study investigating pharmacokinetic properties of BT524 and efficacy and safety of BT524 in the treatment and prophylaxis of bleeding in patients with congenital fibrinogen deficiency	A prospective, open-label, phase I/II study investigating pharmacokinetic properties of BT524 and efficacy and safety of BT524 in the treatment and prophylaxis of bleeding in patients with congenital fibrinogen deficiency	Patients with congenital afibrinogenemia or severe congenital hypofibrinogenemia. MedDRA version: 14.1;Level: PT;Classification code 10016075;Term: Factor I deficiency;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]	Product Name: Fibrinogen Concentrate from Human Plasma Product Code: BT524 INN or Proposed INN: Human Fibrinogen Concentrate Other descriptive name: Human Fibrinogen Concentrate	Biotest AG	NULL	Not Recruiting			Female: yes Male: yes	20	Phase 1;Phase 2	Egypt;Lebanon;Germany;Italy
2	EUCTR2007-004088-22-DE (EUCTR)	14/04/2011	27/07/2010	Efficacy and safety of Fibrinogen Concentrate (Human) for on-demand treatment of acute bleeding in subjects with congenital fibrinogen deficiencyFibrinogen Concentrate (Human) (FCH) - efficacy and safety	Efficacy and safety of Fibrinogen Concentrate (Human) for on-demand treatment of acute bleeding in subjects with congenital fibrinogen deficiencyFibrinogen Concentrate (Human) (FCH) - efficacy and safety	Congenital fibrinogen deficiency (afibrinogenemia, severe hypofibrinogenemia) MedDRA version: 12.0;Level: LLT;Classification code 10016075;Term: Factor I deficiency	Trade Name: Haemocomplettan(R) P 1g/2g Product Name: Haemocomplettan(R) P INN or Proposed INN: Fibrinogen (coagulation factorI) Other descriptive name: HUMAN FIBRINOGEN	CSL Behring GmbH	NULL	Not Recruiting			Female: yes Male: yes	23		Germany;Italy
3	EUCTR2006-006023-39-IT (EUCTR)	24/09/2007	12/06/2007	Pharmacokinetics of Haemocomplettan P in subjects with congenital fibrinogen deficiency - ND	Pharmacokinetics of Haemocomplettan P in subjects with congenital fibrinogen deficiency - ND	PK study in patient with afibrinogemia MedDRA version: 9.1;Level: LLT;Classification code 10016075;Term: Factor I deficiency	Trade Name: Haemocomplettan P	CSL Behring GmbH	NULL	Not Recruiting			Female: yes Male: yes			Italy